Zoledronate (INN: zoledronic acid, marketed by Novartis under the trade names Zometa® and Aclasta®) is a bisphosphonate. Zometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases.